RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0041-1732342
Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
Abstract
An 84 year old male with a previous history of immune thrombotic thrombocytopenic purpura (iTTP) received the first dose of COVID19 mRNA vaccine (Pfizer-Biontech). Seven days later he was diagnosed with iTTP relapse. He received in-patient treatment with therapeutic plasma exchange, high dose steroids and rituximab and subsequently recovered. This case report highlights the need to monitor patients with iTTP following vaccination.
Publikationsverlauf
Eingereicht: 01. Juni 2021
Angenommen: 18. Juni 2021
Artikel online veröffentlicht:
09. August 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Cuker A, Cataland SR, Coppo P. et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood 2021; 137 (14) 1855-1861
- 2 Vaccination YI, Purpura TT. Turk J Haematol 2020; 37 (03) 218-219
- 3 Sissa C, Al-Khaffaf A, Frattini A. et al. Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine. Transfus Apher Sci. 2021
- 4 Franchini M, Liumbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol 2021; ••• : Epub ahead of print
- 5 Yocum A, Simon EL. Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination. Am J Emerg Med 2021; S0735-6757 (21)00376-4